The Menzies Institute for Medical Research is an Australian medical research institute of the University of Tasmania based in Hobart, Tasmania.

During the past decade, Menzies Institute for Medical Research conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 6 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Menzies Institute for Medical Research" #1 sponsor was "Amgen" with 4 trials, followed by "Menzies Institute for Medical Research" with 4 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Clene Nanomedicine" with 1 trials sponsored and "Endo Pharmaceuticals" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Menzies Institute for Medical Research" #1 collaborator was "Clene Australia Pty Ltd" with 1 trials as a collaborator, "Deakin University" with 1 trials as a collaborator, "Department of Health Tasmania" with 1 trials as a collaborator, "Diagnostic Services Pty Ltd" with 1 trials as a collaborator and "Healthcare Software Pty Ltd" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Menzies Institute for Medical Research" are "Psoriatic Arthritis" (4 trials), "Rheumatoid Arthritis" (3 trials), "Ankylosing Spondyloarthritis" (1 trials), "Cardiovascular Diseases" (1 trials) and "Dupuytren's Disease" (1 trials). Many other conditions were trialed in "Menzies Institute for Medical Research" in a lesser frequency.

Most popular intervention types in "Menzies Institute for Medical Research" are "Drug" (10 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Apremilast 20mg" (2 trials), "Apremilast 30mg" (2 trials), "Adalimumab" (1 trials) and "Allogeneic Mesenchymal Precursor Cells" (1 trials). Other intervention names were less common.

The vast majority of trials in "Menzies Institute for Medical Research" are 14 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Menzies Institute for Medical Research". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Menzies Institute for Medical Research, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Menzies Institute for Medical Research, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".